Orphagen Pharmaceuticals
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
11558 Sorrento Valley Rd Ste 4, San Dieg...Phone Number
(858) 481-6191Website
www.orphagen.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Orphagen Pharmaceuticals
Orphagen Pharmaceuticals specializes in the discovery of small molecule medicines, focusing on orphan nuclear receptors to develop novel therapies for cancer and other serious diseases. Their drug candidates target members of the nuclear receptor superfamily, with advanced programs in oncology and treatments for inflammatory bowel diseases. The company is dedicated to translational drug discovery and actively engages with clinical, scientific, investment, and patient communities. Orphagen's mission is to deliver first-in-class therapeutics through innovative research and development.Explore more
Orphagen Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Orphagen Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Orphagen Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Orphagen Pharmaceuticals had a recent Job posting/layoffs
Check out if Orphagen Pharmaceuticals is spiking on competitors!
Orphagen Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Orphagen Pharmaceuticals has new funding data
Product Launch: Get notified when Orphagen Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Orphagen Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Orphagen Pharmaceuticals
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Orphagen Pharmaceuticals
Compare insights from companies similar to Orphagen Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Orphagen Pharmaceuticals
<$5M
1-10
Private
<$5M
2000
TS
Theodore St. MartinVice President, Finance & Consultant
Company Profile Activity
Activity Insights
Orphagen Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Orphagen Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Orphagen Pharmaceuticals.
Orphagen Pharmaceuticals financials insights
Gather financial insights about Orphagen Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
Orphagen Pharmaceuticals Tech Stack
A closer look at the technologies used by Orphagen Pharmaceuticals
See more technologies
Orphagen Pharmaceuticals News & Media
Orphagen Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for OR-449 for the Treatment of Pediatric Adrenocortical Carcinoma
SAN DIEGO--(BUSINESS WIRE)--Orphagen Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for OR-449 for the Treatment of Pediatric Adrenocortical CarcinomaOrphagen Pharmaceuticals Presents Data on Downstream Targets of SF-1 Antagonist OR-449 at ENDO 2022
SAN DIEGO--(BUSINESS WIRE)--Orphagen Pharmaceuticals Presents Data on Downstream Targets of SF-1 Antagonist OR-449 at ENDO 2022Orphagen Pharmaceuticals Presents Preclinical Efficacy Data at AACR 2022 on OR-449, a First-in-Class Steroidogenic Factor 1 Inhibitor, for the Treatment of Leydig Cell Tumors
SAN DIEGO--(BUSINESS WIRE)-- #AACR22--Orphagen Presents Preclinical Efficacy Data at AACR 2022 on OR-449, a First-in-Class SF-1 Inhibitor, for the Treatment of Leydig Cell TumorsScientist.com and Orphagen Pharmaceuticals Partner to Offer Online...
Marketplace users now have access to cell and biochemical assays for orphan nuclear receptor translational research (PRWeb August 06, 2018) Read the full story at https://www.prweb.com/releases/scientist_com_and_orphagen_pharmaceuticals_partner_to_offer_online_access_to_nuclear_receptor_profiling_and_screening_services/prweb15670191.htm
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Orphagen Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Orphagen Pharmaceuticals specializes in the discovery of small molecule medicines, focusing on orphan nuclear receptors to develop novel therapies for cancer and other serious diseases. Their drug candidates target members of the nuclear receptor superfamily, with advanced programs in oncology and treatments for inflammatory bowel diseases. The com... Read More
